At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BHVN Biohaven Pharmaceutical Holding Co Ltd.
Post-Mkt 08-31 16:35:35 EDT
15.27
-0.14
-0.91%
盘后15.27
+0.00+0.00%
16:29 EDT
High15.79Low15.18Vol2.93M
Open15.46D1 Closing15.41Amplitude3.99%
Mkt Cap2.30BTradable Cap1.80BTotal Shares150.42M
T/O45.14MT/O Rate2.48%Tradable Shares117.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal?
Simply Wall St.  ·  08-31 19:21
Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal?
Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal
MT Newswires Live  ·  08-27
Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS) and Biohaven Ltd. (BHVN)
TIPRANKS  ·  08-27
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS) and Biohaven Ltd. (BHVN)
H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’
TIPRANKS  ·  08-27
H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’
Biohaven rises 10.8%
TIPRANKS  ·  08-27
Biohaven rises 10.8%
Biohaven Shares Gain 5% on SK Biopharma Epilepsy Licensing Deal Worth up to $795 Million
THOMSON REUTERS  ·  08-26
Biohaven Shares Gain 5% on SK Biopharma Epilepsy Licensing Deal Worth up to $795 Million
U.S. Stocks on the MOVE-Semtech, Donaldson, Meta
Reuters  ·  08-26
U.S. Stocks on the MOVE-Semtech, Donaldson, Meta
Delaware Court Enters USD 4 Million Judgment for Biohaven, Yale in Trade Secret Case Against RA Capital, Avilar
Reuters  ·  08-26
Delaware Court Enters USD 4 Million Judgment for Biohaven, Yale in Trade Secret Case Against RA Capital, Avilar
Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact
TIPRANKS  ·  08-26
Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact
Biohaven Licenses Kv7 Epilepsy Drug Platform to SK Biopharmaceuticals in Deal Worth up to USD 795 Million
Reuters  ·  08-26
Biohaven Licenses Kv7 Epilepsy Drug Platform to SK Biopharmaceuticals in Deal Worth up to USD 795 Million
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
THOMSON REUTERS  ·  08-26
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Biohaven - SK Biopharmaceuticals to Pay up to $795 Mln Plus Tiered U.S. Royalties to Biohaven
THOMSON REUTERS  ·  08-26
Biohaven - SK Biopharmaceuticals to Pay up to $795 Mln Plus Tiered U.S. Royalties to Biohaven
Biohaven - to Receive $400 Mln Cash, Including $350 Mln at Closing and $50 Mln in 2027
THOMSON REUTERS  ·  08-26
Biohaven - to Receive $400 Mln Cash, Including $350 Mln at Closing and $50 Mln in 2027
Biohaven - Eligible for $150 Mln in Development and Regulatory Milestones Plus Global Royalties
THOMSON REUTERS  ·  08-26
Biohaven - Eligible for $150 Mln in Development and Regulatory Milestones Plus Global Royalties
Biohaven Receives Favorable Ruling in the Trade Secret Misappropriation Lawsuit
MT Newswires Live  ·  08-26
Biohaven Receives Favorable Ruling in the Trade Secret Misappropriation Lawsuit
Biohaven - Federal Court Confirms Ra Capital and Avilar Therapeutics "Misappropriated" Yale Trade Secret
THOMSON REUTERS  ·  08-26
Biohaven - Federal Court Confirms Ra Capital and Avilar Therapeutics "Misappropriated" Yale Trade Secret
Biohaven - U.S. District Court Awards $4 Mln to Biohaven and Yale in Trade Secret Case
THOMSON REUTERS  ·  08-26
Biohaven - U.S. District Court Awards $4 Mln to Biohaven and Yale in Trade Secret Case
Biohaven Files Form 3 Initial Beneficial Ownership Statement for Director John Yetimoglu
Reuters  ·  08-15
Biohaven Files Form 3 Initial Beneficial Ownership Statement for Director John Yetimoglu
Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says
MT Newswires Live  ·  08-11
Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says
RBC Adjusts Price Target on Biohaven to $23 From $22, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  08-11
RBC Adjusts Price Target on Biohaven to $23 From $22, Maintains Outperform Speculative Risk Rating

Introduction

Company Name.
Biohaven Pharmaceutical Holding Co Ltd.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Issue price:
--